Login / Signup

CD8 + T cell differentiation status correlates with the feasibility of sustained unresponsiveness following oral immunotherapy.

Abhinav KaushikDiane DunhamXiaorui HanEvan DoSandra AndorfSheena GuptaAndrea FernandesLaurie Elizabeth KostSayantani B SindherWong YuMindy TsaiRobert TibshiraniScott D BoydManisha DesaiHolden T MaeckerStephen J GalliRebecca Sharon ChinthrajahRosemarie H DeKruyffMonali ManoharKari Christine Nadeau
Published in: Nature communications (2022)
While food allergy oral immunotherapy (OIT) can provide safe and effective desensitization (DS), the immune mechanisms underlying development of sustained unresponsiveness (SU) following a period of avoidance are largely unknown. Here, we compare high dimensional phenotypes of innate and adaptive immune cell subsets of participants in a previously reported, phase 2 randomized, controlled, peanut OIT trial who achieved SU vs. DS (no vs. with allergic reactions upon food challenge after a withdrawal period; n = 21 vs. 30 respectively among total 120 intent-to-treat participants). Lower frequencies of naïve CD8 + T cells and terminally differentiated CD57 + CD8 + T cell subsets at baseline (pre-OIT) are associated with SU. Frequency of naïve CD8 + T cells shows a significant positive correlation with peanut-specific and Ara h 2-specific IgE levels at baseline. Higher frequencies of IL-4 + and IFNγ + CD4 + T cells post-OIT are negatively correlated with SU. Our findings provide evidence that an immune signature consisting of certain CD8 + T cell subset frequencies is potentially predictive of SU following OIT.
Keyphrases
  • immune response
  • phase iii
  • phase ii
  • open label
  • peripheral blood
  • double blind
  • dendritic cells
  • study protocol
  • randomized controlled trial
  • risk assessment
  • human health
  • climate change
  • allergic rhinitis